PTGS2 and chronic myelogenous leukemia, BCR-ABL1 positive: In addition to HCQ, celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, has demonstrated potential anti-tumor benefits in solid tumors and has recently been examined for its anti-CML properties.